All In Biotech

Drug Trial Radar · NCT06243614

Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Safety and Efficacy of Buagafuran Capsules in the Treatment of Generalized Anxiety Disorder: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Flexible-dose Phase Ⅲ Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

Jun 30, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
R&G Pharma Studies Co.,Ltd.
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • Buagafuran capsules, 15mg/ capsuleDrug

    Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

  • Buspirone tablets, 5mg/ tabletDrug

    Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.

  • Buagafuran capsules mimic, 0mg/ capsuleDrug

    Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

  • Buspirone tablets mimic, 0mg/ tabletDrug

    Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hamilton anxiety scale score after treatmentTime frame: the end of week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Union Pharmaceutical Factory Ltd

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.